Every 10-Q that QUARTA-RAD INC (QURT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QURT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QURT filings page.
Quarta-Rad, Inc. reported a consolidated net loss of $34,785 for the quarter ended June 30, 2026, improved from a loss of $72,095 a year earlier, on revenue of $63,856 versus $67,330. For the first six months of 2026, revenue was $89,712 and net loss was $138,963, compared with $100,217 and $149,504, respectively, in 2025.
Total assets were $367,030 at June 30, 2026, largely a $302,367 related-party note and interest receivable tied to land in Thailand, while cash was $38,528. Liabilities totaled $363,458, leaving stockholders’ equity of only $3,572 and a working capital deficit of $309,030.
The company has substantial doubt about its ability to continue as a going concern due to recurring losses, negative operating cash flow, and limited liquidity. Nearly all revenue ($63,000 of $63,856 in Q2) comes from Sellavir’s software and consulting services to STAR, a related-party Japanese reseller with no volume commitments; loss of this relationship would eliminate substantially all revenue. Management is winding down the legacy radiation detection business and focusing on Sellavir’s AI-driven CenterEye call-center platform, including a non-exclusive AppFoundry partnership with Genesys that has not yet generated revenue. Internal control over financial reporting is deemed ineffective, with multiple material weaknesses and no independent directors or audit committee.
Quarta-Rad, Inc. reported a net loss of $104,178 for the three months ended March 31, 2026, wider than the $77,409 loss a year earlier, on net sales of $25,856. Revenue fell as the company continued winding down its legacy radiation detection products and focused on Sellavir’s AI-driven CenterEye call-center software.
Operating expenses rose to $101,147, largely from Sellavir-related costs and stock-based compensation of $18,553. Cash declined to $14,568, and working capital showed a deficit of $293,847. Management disclosed recurring losses and an accumulated deficit of about $532,500, concluding that these factors raise “substantial doubt” about Quarta-Rad’s ability to continue as a going concern.
Total assets were $366,779, including a related-party note receivable of $254,719 tied to Thai real estate, which generated a foreign currency loss of $10,053. The company relies heavily on related-party revenue and support, has no bank financing, and reported material weaknesses in internal control over financial reporting, including insufficient segregation of duties and limited technical accounting expertise.
Quarta-Rad, Inc. (QURT) reported Q3 2025 results. Net revenue was $62,469 and net loss was $66,641. The quarter was driven by Sellavir service revenue of $60,000, while the legacy Quarta-Rad hardware business contributed $2,469. Operating expenses rose to $94,747, including $55,656 of stock-based compensation.
For the nine months ended September 30, 2025, net revenue totaled $162,686 and net loss was $216,145. Segment results show Quarta-Rad revenue of $7,686 and Sellavir revenue of $155,000 for the period. Cash was $33,108 as of September 30, 2025, with a working capital deficit of $228,153. Stockholders’ equity was $109,110, and 15,899,483 shares were outstanding as of November 13, 2025.
Management disclosed substantial doubt about the company’s ability to continue as a going concern due to recurring losses and limited revenues. The company is shifting focus toward Sellavir’s AI-driven call center software, CenterEye, and disclosed related-party loans and revenues consistent with prior operations.